<p>PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer</p>

Xiao Fu(First Affiliated Hospital of Xi'an Jiaotong University), Yu Yao(First Affiliated Hospital of Xi'an Jiaotong University), Xiaoqiang Zheng(First Affiliated Hospital of Xi'an Jiaotong University), Zhiping Ruan(First Affiliated Hospital of Xi'an Jiaotong University), Aimin Jiang(First Affiliated Hospital of Xi'an Jiaotong University), Na Liu(First Affiliated Hospital of Xi'an Jiaotong University), Jingjing Wang(First Affiliated Hospital of Xi'an Jiaotong University), Mengjie Liu(First Affiliated Hospital of Xi'an Jiaotong University), Huan Gao(First Hospital of Jilin University), Xuan Liang(First Affiliated Hospital of Xi'an Jiaotong University), Yujuan Yang(Shanghai Jiao Tong University), Zhiyan Liu(Northwest University), Luochengling Xiang(First Affiliated Hospital of Xi'an Jiaotong University), Tao Tian(Hebei Medical University)
Cancer Management and Research
October 1, 2020
10.2147/cmar.s260599
Cited by 14

Related Papers

RETRACTED ARTICLE: Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway
|Journal of Experimental & Clinical Cancer Research|2018|222
Micro<scp>RNA</scp>‐155‐5p promotes hepatocellular carcinoma progression by suppressing <scp>PTEN</scp> through the <scp>PI</scp>3K/Akt pathway
|Cancer Science|2017|166
Consensus for HER2 alterations testing in non-small-cell lung cancer
|ESMO Open|2022|110
Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring
|Annals of Hematology|2010|100
miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer
|Oncology Reports|2015|84